Jun 20, 2026The way we write and say ‘health care’—as one word or two—is not just a matter of style, but of meaning and identity. As discussions heat up regarding the evolution of the term and its presentation in media, the implications for policy, perception, and professional culture come under fresh scrutiny. This language debate illuminates broader trends in how we define and deliver care in modern society.
Sophia Reynolds
Jun 20, 2026STAT News recently showcased a wide array of reader opinions, particularly focusing on blue zones and open-access publishing fees. These debates shed light on the complex, sometimes contentious, intersections of public health knowledge, research communication, and the incentive structures in modern science. The diversity and depth of views shared by readers reveal enduring disagreements and evolving priorities in biomedicine.
Dr. Alex Morgan
Jun 20, 2026Denali’s high-value deal demonstrates the continued strength of the FDA priority review voucher program following its renewal in 2026. As rare disease and neurodegenerative therapy investments surge, this transaction spotlights broader trends in drug development incentives and the growing market value of regulatory acceleration.
Jonathan Blake
Jun 16, 2026Supplement use in the United States has not remained static. From vitamin C frenzy to the mainstreaming of protein powders and probiotics, each decade has delivered new motivations and products for consumers. This piece traces the evolution, the forces involved, and potential implications for medicine and wellness.
Dr. Alex Morgan 
Jun 16, 2026In a significant industry development, Neumora Therapeutics has elected to abandon its most advanced depression program, sparking a corresponding workforce reduction. The move highlights ongoing volatility in neuropsychiatric drug development and raises questions about the challenges facing biotech firms targeting CNS disorders.
Jonathan Blake 
Jun 14, 2026Rocket Pharmaceuticals has sold its rare pediatric disease priority review voucher for $180 million following FDA’s accelerated approval of Kresladi. The proceeds will provide non-dilutive funding for Rocket’s pipeline, including gene therapies for rare conditions such as Danon disease.
Dr. Alex Morgan 
Jun 12, 2026The pharmaceuticals industry continues to see considerable turbulence, with Genentech’s recent R&D cuts marking both a significant internal realignment and a snapshot of wider sector volatility. Analyzing layoffs, restructuring strategies, and industry response, this in-depth look connects the dots on what these moves mean for Genentech, its workforce, and the future of pharmaceutical research and development.
Sophia Reynolds 
Jun 12, 2026Novo Nordisk communicated that a recent cybersecurity attack resulted in unauthorized access to proprietary clinical trial data, raising concerns about patient privacy and the robustness of data safeguards in the pharmaceutical industry. While Novo maintains that direct identification of trial participants is unlikely, the incident underscores rising cybersecurity risks in biopharma.
Emily Carter
Jun 11, 2026With the discontinuation of a critical investigational cancer therapy, Blood Cancer United’s unprecedented move guarantees continued access for patients in need. This event spotlights the emerging role of advocacy organizations in safeguarding patient interests amidst a dynamic and often volatile pharmaceutical landscape.
Jonathan Blake 
Jun 11, 2026Panelists at the HFMA annual conference delivered a dire message to healthcare financial leaders: the 2030s could bring unprecedented disruption as demographic shifts, shrinking reimbursements, and artificial intelligence rapidly reshape the industry. The window for bold, transformative action is closing fast, with potentially existential consequences for hospitals and health systems.
Daniel Cho
Jun 10, 2026With more than $25 billion spent on acquisitions and ten deals closed just this year, Eli Lilly has asserted itself as the leading biopharma acquirer of the decade. This article delves into the motivations, risks, and implications for the broader life sciences industry as a wave of consolidation unfolds.
Daniel Cho 
Jun 9, 2026GlaxoSmithKline (GSK) has announced a definitive agreement to acquire Nuvalent, a company specializing in targeted cancer drugs. Valued at $10.6 billion, the deal not only reinforces GSK’s strategy to expand its oncology offerings but also highlights ongoing merger and acquisition activity in the sector, as companies race to secure innovative assets with blockbuster potential.
Sophia Reynolds 